Artificial intelligence (AI) is poised to transform inflammatory bowel disease (IBD) care by improving how clinicians interpret complex data, monitor disease progression, and generate real-world evidence for research.
Dr. Christina Awad sits down with Dr. Anna L. Silverman of Mayo Clinic to discuss how AI is shaping the future of IBD management. Drawing on her expertise in gastroenterology, data science, and clinical research, Dr. Silverman explains how machine learning and large language models can unlock valuable insights from unstructured clinical data, automate disease activity scoring from endoscopy reports, and standardize clinical documentation across providers. She also shares how emerging technologies, including intestinal ultrasound and wearable devices, may enable earlier detection of disease flares and more proactive patient care.
Their conversation explores the most promising near-term applications of AI in IBD, including enhancing real-world data for research, improving clinical trial design, supporting treatment monitoring, and streamlining documentation. They also discuss the importance of AI governance, minimizing bias in model development, and maintaining human oversight to ensure these technologies complement rather than replace clinical judgment.